Crypto news

The quantum computing market has long been trapped in a race for abstract metrics — the number of qubits and performance records. However, a new IBM report titled Journey to Quantum Advantage radically shifts the paradigm. Instead of a single technological milestone, the company proposes viewing quantum advantage as the ability to solve specific business problems more accurately, faster, and cheaper than classical algorithms. This is not just a change in wording — it is a pragmatic look at real-world implementation.

What Drives Business?

The report, based on interviews with representatives from aerospace, finance, energy, and biomedicine, identified three key drivers. 60% of companies are seeking solutions for complex business problems, 55% are preparing their computing strategy for future changes, and 54% aim to accelerate innovation. This directly indicates that quantum technologies are ceasing to be a laboratory curiosity and are becoming part of corporate roadmaps.

However, the path to practical advantage is strewn with barriers. The main problem is a catastrophic shortage of qualified personnel (61% of respondents). Next come the immaturity of the technology itself (56%) and uncertainty about the timeline for the emergence of applied scenarios (46%). This is a classic "chicken or egg" dilemma: without specialists, there is no progress, and without progress, there is no point in hiring specialists.

Real-World Cases: From Boeing to Biomedicine

The examples from the report are telling. Boeing views quantum computing not as an abstraction, but as a tool for quantum chemistry and materials science — for designing and certifying aircraft. Since 2022, Vanguard has been testing hybrid approaches for anti-money laundering and portfolio optimization. Notably, Vanguard's lead researcher stated outright that advantage only makes sense when it helps clients, not when it merely demonstrates a technological frontier.

E.ON and Bosch went through disappointment in early experiments. Limited circuit depth, noise, and a small number of qubits prevented them from surpassing classical methods. As a result, both companies adjusted their roadmaps towards long-term preparation for fault-tolerant systems. This is a sobering signal for those expecting an instant revolution.

In biomedicine, the situation is encouraging. Yonsei University uses quantum resources alongside supercomputers to study mitochondrial processes. Even reducing drug development timelines by 10-20% (from the current 15 years) could radically transform the industry. And in April 2026, the Quantum Pangenomics team loaded the complete genome of the hepatitis D virus onto a 156-qubit IBM Heron processor — this is no longer theory, but a practical step.

Ecosystem as a Key Factor

IBM rightly emphasizes that quantum readiness is not just about technology, but also about partnerships. Every second "quantum-ready" organization participates in alliances with business, government, and universities. Examples include Volkswagen, Chicago State University, Bradesco, and Singapore. The current stage of the market is a period of experimentation and competency building, not mass adoption.

My conclusion: The IBM report is a cold shower for enthusiasts, but fresh air for pragmatists. Quantum advantage will not arrive "tomorrow" for all industries simultaneously. It will come in waves, starting with narrow but critically important tasks. Investors and businesses that now focus on developing competencies and finding specific scenarios, rather than racing for qubits, will find themselves in a winning position.